Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor

Molecular Cancer Therapeutics

Volumn 10, Issue 4, 2011, Pages 670-678

  Hattori, Hiroyoshi ^a   Skoulidis, Ferdinandos ^a   Russell, Paul ^a   Venkitaraman, Ashok R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; CHECKPOINT KINASE 1; GEMCITABINE; MITOMYCIN C;

ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL CYCLE S PHASE; CELL GROWTH; CELL STRAIN HEK293; GENE IDENTIFICATION; GENE TARGETING; GENETICS; HUMAN; HUMAN CELL; MOUSE; MUTANT; NONHUMAN; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; BLOTTING, WESTERN; BRCA2 PROTEIN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; MICE; MUTATION; PANCREATIC NEOPLASMS; PROTEIN KINASES; RAS PROTEINS; RNA INTERFERENCE; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 79955758170     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0781     Document Type: Article

References (35)

1. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001;7:263-72. (Pubitemid 32206494)
2. Venkitaraman AR. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 2009;4:461-87.
3. Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, et al. Involvement of Brca2 in DNA repair. Mol Cell 1998;1:347-57. (Pubitemid 128378883)
4. Yu VP, Koehler M, Steinlein C, Schmid M, Hanakahi LA, van Gool AJ, et al. Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev 2000;14:1400-6. (Pubitemid 30397083)
5. Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998;90:978-85. (Pubitemid 28340438)
6. Evers B, Schut E, Van Der Burg E, Braumuller TM, Egan DA, Holstege H, et al. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res 2010;16:99-108.
7. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997;278:1064-8. (Pubitemid 27517876)
8. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98.
9. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7. (Pubitemid 40559005)
10. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21. (Pubitemid 40559006)
11. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
12. Kennedy RD, Chen CC, Stuckert P, Archila EM, De la Vega MA, Moreau LA, et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007;117:1440-9. (Pubitemid 46718432)
13. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003;95:214-21. (Pubitemid 36240634)
14. Couch FJ, Johnson MR, Rabe KG, Brune K, de Andrade M, Goggins M, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007;16:342-6. (Pubitemid 46383356)
15. Caldas C, Kern SE. K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 1995;18:1-6.
16. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33. (Pubitemid 24187791)
17. Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, et al. Germline Brca2 heterozygosity promotes Kras (G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 2010;18:499-509.
18. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9. (Pubitemid 34815345)
19. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010;16:376-83.
20. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107-17.
21. Knight ZA, Shokat KM. Chemical genetics: where genetics and pharmacology meet. Cell 2007;128:425-30. (Pubitemid 46198904)
22. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88:956-65. (Pubitemid 26239383)
23. Wang GT, Li G, Mantei RA, Chen Z, Kovar P, Gu W, et al. 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities. J Med Chem 2005;48:3118-21. (Pubitemid 40628030)
24. Chen CC, Kennedy RD, Sidi S, Look AT, D'Andrea A. CHK1 inhibition as a strategy for targeting Fanconi anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 2009;8:24.
25. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 20,20-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110-7.
26. Ostruszka LJ, Shewach DS. The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine. Cancer Res 2000;60:6080-8.
27. Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, et al. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med 2009;7:43.
28. McNeely S, Conti C, Sheikh T, Patel H, Zabludoff S, Pommier Y, et al. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle 2010;9:995-1004.
29. Toulany M, Kehlbach R, Florczak U, Sak A, Wang S, Chen J, et al. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 2008;7:1772-81.
30. Sklar MD. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 1988;239:645-7. (Pubitemid 18066229)
31. Bernhard EJ, Stanbridge EJ, Gupta S, Gupta AK, Soto D, Bakanauskas VJ, et al. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 2000;60:6597-600.
32. Chang IY, Youn CK, Kim HB, Kim MH, Cho HJ, Yoon Y, et al. Oncogenic H-Ras up-regulates expression of Ku80 to protect cells from gamma-ray irradiation in NIH3T3 cells. Cancer Res 2005;65:6811-9. (Pubitemid 41060719)
33. Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA, et al. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood 2008;112:2439-49.
34. Venkitaraman AR. Tracing the network connecting BRCA and Fanconi anaemia proteins. Nat Rev Cancer 2004;4:266-76. (Pubitemid 38525282)
35. Van Der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005;11:7508-15.